Amorphous Calcium Carbonate Shows Anti-Cancer Properties That are Attributed to Its Buffering Capacity

• Published in: Cancers 2023-07, Vol.15 (15), p.3785
• Main Authors: Natan, Yehudit, Blum, Yigal Dov, Arav, Amir, Poliansky, Ylena, Neuman, Sara, Ecker Cohen, Orit, Ben, Yossi
• Format: Article
• Language: English
• Subjects: Acidity; Acidosis; Acids; Analysis; Angiogenesis; Bioavailability; Calcium carbonate; Cancer; Cancer therapies; Care and treatment; Cathepsin B; Cathepsins; Cell culture; Chemotherapy; Cisplatin; Clinical trials; Colon cancer; Development and progression; Drug therapy; Experiments; Gene expression; Glycolysis; Health aspects; Immune system; Lung cancer; Lung carcinoma; Metabolism; Metastasis; Microenvironments; Nanoparticles; Prostate cancer; Solid tumors; Therapeutic targets; Tumors; Xenografts
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers15153785

Amorphous calcium carbonate (ACC) is a non-crystalline form of calcium carbonate, and it is composed of aggregated nano-size primary particles. Here, we evaluated its anti-cancer effect postulated relative to its buffering capabilities in lung cancer. Tumors were evaluated in vivo using the Lewis lung carcinoma (LLC) mouse cell line and A549 human lung cancer carcinoma cell line. LLC and A549 cells were injected subcutaneously into the right hind leg of mice. Treatments (ACC, cisplatin, vehicle, and ACC with cisplatin, all given via daily IP injections) started once tumors reached a measurable size. Treatments were carried out for 14 days in the LLC model and for 22 and 24 days in the xenograft model (two experiments). LLC tumors were resected from ACC at the end of the study, and vehicle groups were evaluated for cathepsin B activity. Differential gene expression was carried out on A549 cells following 8 weeks of in vitro culture in the presence or absence of ACC in a culture medium. The ACC treatment decelerated tumor growth rates in both models. When tumor volumes were compared on the last day of each study, the ACC-treated animal tumor volume was reduced by 44.83% compared to vehicle-treated animals in the LLC model. In the xenograft model, the tumor volume was reduced by 51.6% in ACC-treated animals compared to vehicle-treated animals. A more substantial reduction of 74.75% occurred in the combined treatment of ACC and cisplatin compared to the vehicle (carried out only in the LLC model). Cathepsin B activity was significantly reduced in ACC-treated LLC tumors compared to control tumors. Differential gene expression results showed a shift towards anti-tumorigenic pathways in the ACC-treated A549 cells. This study supports the ACC anti-malignant buffering hypothesis by demonstrating decelerated tumor growth, reduced cathepsin B activity, and altered gene expressions to produce anti-cancerous effects.